Advertisement

Topics

UniQure Names McMillan COO, van Deventer Succeeds Retiring CSO

18:47 EDT 8 Aug 2017 | Xconomy

Scott McMillan is joining uniQure (NASDAQ: QURE) as chief operating officer. Before coming to uniQure, a gene therapy developer split between The Netherlands and Lexington, MA, McMillan was senior vice president of quality and technical operations at AMAG Pharmaceuticals (NASDAQ: AMAG) in Waltham, MA. McMillan will be based at uniQure’s Lexington site. In other moves, […]

Original Article: UniQure Names McMillan COO, van Deventer Succeeds Retiring CSO

NEXT ARTICLE

More From BioPortfolio on "UniQure Names McMillan COO, van Deventer Succeeds Retiring CSO"

Quick Search
Advertisement
 

Relevant Topic

Gene Therapy
Gene therapy is the use of DNA as a pharmaceutical agent to treat disease. It derives its name from the idea that DNA can be used to supplement or alter genes within an individual's cells as a therapy to treat disease. The most common form of gene th...